Fiflis S, Papakonstantinou M, Giakoustidis A, Christodoulidis G, Louri E, Papadopoulos VN, Giakoustidis D. Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review. World J Gastrointest Surg 2023; 15(8): 1808-1818 [PMID: 37701690 DOI: 10.4240/wjgs.v15.i8.1808]
Corresponding Author of This Article
Gregory Christodoulidis, PhD, Surgeon, Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. gregsurg@yahoo.gr
Research Domain of This Article
Surgery
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Stylianos Fiflis, Menelaos Papakonstantinou, Alexandros Giakoustidis, Eleni Louri, Vasileios N Papadopoulos, Dimitrios Giakoustidis, A’ Department of Surgery, General Hospital Papageorgiou, Thessaloniki 56429, Greece
Gregory Christodoulidis, Department of General Surgery, University Hospital of Larissa, Larissa 41110, Greece
Author contributions: Fiflis S designed and performed the research and wrote most of the manuscript; Papakonstantinou M performed the research, analyzed the data and wrote part of the results and the discussion; Giakoustidis A resolved conflicts during the article screening, offered guidance and performed manuscript revisions; Christodoulidis G perceived the idea, performed manuscript revisions and assisted as a corresponding author; Louri E wrote part of the discussion and performed manuscript revisions; Papadopoulos VN performed manuscript revisions; Giakoustidis D offered guidance and assisted as a supervising author; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 checklist, and the manuscript was prepared and revised according to the PRISMA 2009 checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gregory Christodoulidis, PhD, Surgeon, Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. gregsurg@yahoo.gr
Received: April 24, 2023 Peer-review started: April 24, 2023 First decision: June 1, 2023 Revised: June 7, 2023 Accepted: June 27, 2023 Article in press: June 27, 2023 Published online: August 27, 2023
Core Tip
Core Tip: Gastric cancer (GC) is a major concern worldwide. According to Globocan there were 1089000 new cases of GC and 768000 GC related deaths worldwide in 2020 with almost twice the prevalence and mortality in males than in females. The highest prevalence is observed in Eastern Asia whereas the lowest in Africa. Gastrectomy is the mainstay approach in patients that can undergo surgery and in recent years with the advances in chemotherapy, neoadjuvant chemotherapy (NAT) has shown potential for better survival chances. That is particularly relevant in patients with locally advanced GC as NAT could potentially lead to tumor downsizing thus allowing for higher complete resection rate. In our review we compare patients receiving NAT and then undergoing D2 gastrectomy to those undergoing upfront surgery.
